Stockscreener 앱 받기
0.8031
5.67%
0.0431
시간 외 거래:
.77
-0.0331
-4.12%
Milestone Pharmaceuticals Inc 주식(MIST)의 최신 뉴스
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst - TradingView
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen - Yahoo Finance
Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by TD Securities to Hold - Defense World
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty By Investing.com - Investing.com South Africa
HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating - MarketScreener
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright - TipRanks
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen - Investing.com India
HC Wainwright Reaffirms “Buy” Rating for Milestone Pharmaceuticals (NASDAQ:MIST) - Defense World
Milestone CRL affirms integrity of clinical data, says H.C. Wainwright - Yahoo Finance
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive - NewsBreak: Local News & Alerts
Sector Update: Health Care Stocks Mixed Friday Afternoon - TradingView
Sector Update: Health Care - TradingView
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve - Reuters
Milestone Pharmaceuticals: Buy Rating Affirmed Despite CARDAMYST Approval Delay, Strong Market Potential and Robust Financial Position - TipRanks
Milestone Pharmaceuticals (MIST) Receives FDA Response on Etripa - GuruFocus
Milestone flagging following CRL - The Pharma Letter
Piper Sandler Adjusts Price Target on Milestone Pharmaceuticals to $4 From $5, Maintains Overweight Rating - Marketscreener.com
Milestone Pharma says FDA declined to approve heart disorder therapy - MSN
Milestone Pharmaceuticals Says FDA Cites Manufacturing Concerns for Etripamil NDA; Shares Fall - Marketscreener.com
FDA Declines Milestone Pharmaceuticals' (MIST) Heart Drug Approval - GuruFocus
Manufacturing issues trip up Milestone's long-awaited FDA landmark - FiercePharma
Milestone Pharma stock in focus after FDA snub (MIST:NASDAQ) - Seeking Alpha
FDA flags issues with Milestone’s new drug application By Investing.com - Investing.com South Africa
FDA Issues Complete Response Letter For Etripamil For PSVT - Marketscreener.com
Milestone Pharma slumps after FDA declines to approve heart rhythm nasal spray - TradingView
FDA flags issues with Milestone’s new drug application - Investing.com India
Milestone Pharmaceuticals announces FDA issued CRL for etripamil - TipRanks
US FDA declines to approve Milestone's heart rhythm nasal spray - TradingView
FDA Issues Complete Response Letter for Etripamil for PSVT - The Manila Times
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Marketscreener.com
Milestone Pharmaceuticals Inc. Announces FDA Issues Complete Response Letter for Etripamil for PSVT - MarketScreener
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha
HC Wainwright Brokers Decrease Earnings Estimates for MIST - Defense World
Milestone Pharmaceuticals to present clinical data on etripamil - TipRanks
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - The Manila Times
Breakthrough PSVT Treatment Data: Etripamil Proves Effective for Multiple Episodes - StockTitan
Jones Financial Companies Lllp Raises Stake in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) - Defense World
HC Wainwright Has Negative Outlook of MIST FY2028 Earnings - Defense World
Milestone Pharmaceuticals sets annual meeting date - Investing.com
Milestone Pharmaceuticals sets annual meeting date By Investing.com - Investing.com UK
PDUFA Date Nearing for New PSVT Drug - Streetwise Reports
Milestone Pharma Expands Sale Agreement, Increases Offering By Investing.com - Investing.com Canada
SEC Form 424B5 filed by Milestone Pharmaceuticals Inc. - Quantisnow
Milestone Pharmaceuticals enters open market sale agreement with Jefferies -March 18, 2025 at 05:51 pm EDT - Marketscreener.com
Milestone Pharma Expands Sale Agreement, Increases Offering - Investing.com India
Milestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC Wainwright - Defense World
Milestone Pharmaceuticals: Buy Rating Backed by Promising FDA Approval and Market Expansion Prospects - TipRanks
Optimistic Buy Rating for Milestone Pharmaceuticals Driven by Strategic Plans and Financial Strength - TipRanks
Milestone Pharmaceuticals Eyes FDA Approval for CARDAMYST - TipRanks
Milestone Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Milestone Pharmaceuticals Awaits FDA Decision on CARDAMYST, Prepares for Mid-2025 Launch - TipRanks
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - The Manila Times
Milestone Pharmaceuticals Inc Full Year Loss Decreases, But Misses Estimates - Nasdaq
Milestone Pharmaceuticals Inc. SEC 10-K Report - TradingView
2.00%
자본화:
|
볼륨(24시간):